MA43940A - Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine - Google Patents
Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaineInfo
- Publication number
- MA43940A MA43940A MA043940A MA43940A MA43940A MA 43940 A MA43940 A MA 43940A MA 043940 A MA043940 A MA 043940A MA 43940 A MA43940 A MA 43940A MA 43940 A MA43940 A MA 43940A
- Authority
- MA
- Morocco
- Prior art keywords
- dicarboxamide
- pyridinone
- bromodomain inhibitor
- bromodomain
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562213137P | 2015-09-02 | 2015-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43940A true MA43940A (fr) | 2018-12-12 |
Family
ID=56943472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043940A MA43940A (fr) | 2015-09-02 | 2016-08-31 | Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10428026B2 (fr) |
| EP (1) | EP3344615A1 (fr) |
| JP (1) | JP6532599B2 (fr) |
| KR (1) | KR102088157B1 (fr) |
| CN (1) | CN108137542B (fr) |
| AR (1) | AR105875A1 (fr) |
| AU (1) | AU2016315360B2 (fr) |
| CA (1) | CA2996245C (fr) |
| CL (1) | CL2018000565A1 (fr) |
| CO (1) | CO2018002211A2 (fr) |
| CR (1) | CR20180138A (fr) |
| DO (1) | DOP2018000062A (fr) |
| EA (1) | EA033679B1 (fr) |
| HK (1) | HK1249504A1 (fr) |
| IL (1) | IL257431B (fr) |
| MA (1) | MA43940A (fr) |
| MX (1) | MX2018002699A (fr) |
| PE (1) | PE20181273A1 (fr) |
| PH (1) | PH12018500446A1 (fr) |
| TW (1) | TWI724022B (fr) |
| UY (1) | UY36875A (fr) |
| WO (1) | WO2017037116A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10428026B2 (en) | 2015-09-02 | 2019-10-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridinone dicarboxamide for use as bromodomain inhibitors |
| RU2018112312A (ru) | 2015-09-22 | 2019-10-23 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена |
| BR112018006545A2 (pt) | 2015-10-05 | 2018-10-16 | Glaxosmithkline Ip No 2 Ltd | ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição? |
| EP3440069B1 (fr) | 2016-04-07 | 2020-10-28 | GlaxoSmithKline Intellectual Property (No. 2) Limited | Dérivés de pyridyle en tant qu'inhibiteurs de bromodomaines |
| CA3023765A1 (fr) * | 2016-05-24 | 2017-11-30 | Glaxosmithkline Intellectual Property (No. 2) Limited | Derives de pyridine dicarboxamide utilises comme inhibiteurs de bromodomaine |
| GB201703282D0 (en) | 2017-03-01 | 2017-04-12 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compounds |
| JOP20190192A1 (ar) | 2017-03-01 | 2019-08-08 | Glaxosmithkline Ip No 2 Ltd | مشتقات بيرازول بوصفها مثبطات برومودومين |
| CN108003085A (zh) * | 2017-12-19 | 2018-05-08 | 张开良 | 一种药物中间体芳甲酰基吲哚衍生物的合成方法 |
| CN108484494B (zh) * | 2018-06-15 | 2021-07-30 | 沈阳药科大学 | 2-氧代-1,2-二氢吡啶-4-甲酸类化合物 |
| GB201814167D0 (en) | 2018-08-31 | 2018-10-17 | Glaxosmithkline Ip No 2 Ltd | Compounds |
| MX2022016454A (es) | 2020-06-23 | 2023-03-06 | Genentech Inc | Compuestos macrociclicos y metodos de uso de los mismos. |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1357111E (pt) * | 2000-12-28 | 2009-10-20 | Shionogi & Co | Derivados de 2-piridona com afinidade para receptores de canabinóides do tipo 2 |
| JPWO2003070277A1 (ja) | 2002-02-19 | 2005-06-09 | 塩野義製薬株式会社 | 抗掻痒剤 |
| WO2004033446A1 (fr) | 2002-10-09 | 2004-04-22 | Danter Wayne R | Inhibiteurs de proteine tyrosine kinase |
| TW200412964A (en) | 2002-11-18 | 2004-08-01 | Schering Corp | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| EP1433788A1 (fr) | 2002-12-23 | 2004-06-30 | Aventis Pharma Deutschland GmbH | Dérivés de pyrazole en tant qu'inhibiteurs du facteur Xa |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| TW200700392A (en) | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
| TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
| ES2524787T3 (es) * | 2007-11-15 | 2014-12-12 | Msd Italia S.R.L. | Derivados de piridazinona como inhibidores de PARP |
| EP2306828A4 (fr) * | 2008-06-25 | 2011-06-29 | Glaxosmithkline Llc | Inhibiteurs de prolyl hydroxylases |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| KR20150023722A (ko) | 2012-06-12 | 2015-03-05 | 애브비 인코포레이티드 | 피리디논 및 피리다지논 유도체 |
| ES2615302T3 (es) | 2012-11-08 | 2017-06-06 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con heteroarilo útiles como modulares de cinasa |
| MX2015007921A (es) * | 2012-12-21 | 2016-03-03 | Zenith Epigenetics Corp | Compuestos heterociclicos novedosos como inhibidores de bromodominio. |
| KR20160038008A (ko) | 2013-07-31 | 2016-04-06 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 억제제로서 신규 퀴나졸리논 |
| DE102013215912B3 (de) * | 2013-08-12 | 2015-02-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung |
| US9428514B2 (en) | 2013-12-09 | 2016-08-30 | Abbvie Inc. | Bromodomain inhibitors |
| AR105646A1 (es) | 2015-08-11 | 2017-10-25 | Actelion Pharmaceuticals Ltd | Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida |
| US10428026B2 (en) | 2015-09-02 | 2019-10-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridinone dicarboxamide for use as bromodomain inhibitors |
| BR112018006545A2 (pt) | 2015-10-05 | 2018-10-16 | Glaxosmithkline Ip No 2 Ltd | ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição? |
| EP3440069B1 (fr) | 2016-04-07 | 2020-10-28 | GlaxoSmithKline Intellectual Property (No. 2) Limited | Dérivés de pyridyle en tant qu'inhibiteurs de bromodomaines |
| CA3023765A1 (fr) | 2016-05-24 | 2017-11-30 | Glaxosmithkline Intellectual Property (No. 2) Limited | Derives de pyridine dicarboxamide utilises comme inhibiteurs de bromodomaine |
-
2016
- 2016-08-31 US US15/757,199 patent/US10428026B2/en active Active
- 2016-08-31 CN CN201680059250.XA patent/CN108137542B/zh active Active
- 2016-08-31 TW TW105128127A patent/TWI724022B/zh not_active IP Right Cessation
- 2016-08-31 WO PCT/EP2016/070519 patent/WO2017037116A1/fr active Application Filing
- 2016-08-31 EP EP16766865.6A patent/EP3344615A1/fr active Pending
- 2016-08-31 MX MX2018002699A patent/MX2018002699A/es unknown
- 2016-08-31 KR KR1020187009349A patent/KR102088157B1/ko active IP Right Grant
- 2016-08-31 PE PE2018000339A patent/PE20181273A1/es unknown
- 2016-08-31 AR ARP160102662A patent/AR105875A1/es unknown
- 2016-08-31 JP JP2018511236A patent/JP6532599B2/ja active Active
- 2016-08-31 MA MA043940A patent/MA43940A/fr unknown
- 2016-08-31 EA EA201890331A patent/EA033679B1/ru not_active IP Right Cessation
- 2016-08-31 UY UY0001036875A patent/UY36875A/es not_active Application Discontinuation
- 2016-08-31 CR CR20180138A patent/CR20180138A/es unknown
- 2016-08-31 AU AU2016315360A patent/AU2016315360B2/en not_active Ceased
- 2016-08-31 CA CA2996245A patent/CA2996245C/fr active Active
-
2018
- 2018-02-08 IL IL257431A patent/IL257431B/en active IP Right Grant
- 2018-02-27 CO CONC2018/0002211A patent/CO2018002211A2/es unknown
- 2018-03-01 PH PH12018500446A patent/PH12018500446A1/en unknown
- 2018-03-02 DO DO2018000062A patent/DOP2018000062A/es unknown
- 2018-03-02 CL CL2018000565A patent/CL2018000565A1/es unknown
- 2018-07-11 HK HK18108983.2A patent/HK1249504A1/zh unknown
-
2019
- 2019-08-08 US US16/535,139 patent/US10927080B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43940A (fr) | Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine | |
| IL268282B (en) | hiv inhibitory compounds | |
| SG11201708470SA (en) | Bromodomain inhibitor | |
| KR20180084996A (ko) | 신규 비페닐 화합물 또는 그의 염 | |
| MA52814A (fr) | Inhibiteurs de bromodomaine | |
| MA44006A (fr) | Inhibiteur pde1 | |
| DK3365563T3 (da) | Forbindelseskomponent | |
| MA41977A (fr) | Imidazopyrazinones utilisées comme inhibiteurs de pde1 | |
| DK3373753T3 (da) | Multikomponent-aerosoldannende genstand | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| HK1243948A1 (zh) | 溴結構域抑制劑 | |
| GB201513481D0 (en) | Inhibitor compounds | |
| GB201505658D0 (en) | Inhibitor compounds | |
| MA46280A (fr) | Inhibiteurs de la dopamine-b-hydroxylase | |
| DK3597189T3 (da) | Krystallinske forbindelser | |
| FI20155191A (fi) | Nivel | |
| BR112016019720A2 (pt) | Sistemas inibidor de explosões | |
| DK3504208T3 (da) | Triazolopyrazinon-derivat, der kan anvendes som en human pde1-inhibitor | |
| DE112016002979A5 (de) | Übersteigschutz | |
| MA40429A (fr) | Gabion | |
| DK3342601T3 (da) | Sikkerhedsdokument | |
| DK3168768T3 (da) | Softwarebeskyttelse | |
| DK3112575T3 (da) | Stikforbindelse | |
| EA202190617A3 (ru) | Соединения-ингибиторы бета-лактамаз | |
| DK3245880T3 (da) | Emballeret ost |